Determination of cGMP levels in rodent tissues following oral dosing of a soluble guanylate cyclase stimulator
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2050-6511
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Determination of cGMP levels in rodent tissues following oral dosing of a soluble guanylate cyclase stimulator ; volume:14 ; number:1 ; day:29 ; month:8 ; year:2013 ; pages:1-2 ; date:8.2013
BMC pharmacology & toxicology ; 14, Heft 1 (29.8.2013), 1-2, 8.2013
- Creator
-
Perez, Nisha
- Contributor
-
Graul, Christopher
Germano, Peter
Solberg, Erik
Rivers, Samuel
Solinga, Robert
Moore, Joel
Hannig, Gerhard
Silos-Santiago, Ada
Busby, Robert
Zimmer, Daniel
SpringerLink (Online service)
- DOI
-
10.1186/2050-6511-14-S1-P54
- URN
-
urn:nbn:de:1111-2016073154506
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 11:02 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Perez, Nisha
- Graul, Christopher
- Germano, Peter
- Solberg, Erik
- Rivers, Samuel
- Solinga, Robert
- Moore, Joel
- Hannig, Gerhard
- Silos-Santiago, Ada
- Busby, Robert
- Zimmer, Daniel
- SpringerLink (Online service)
Other Objects (12)
Pharmacokinetics of the soluble guanylate cyclase stimulator riociguat in individuals with hepatic impairment
From molecules to patients: exploring the therapeutic role of soluble guanylate cyclase stimulators
Pharmacokinetics of the soluble guanylate cyclase stimulator riociguat in individuals with renal impairment
Stimulators of soluble guanylate cyclase (sGC) inhibit experimental skin fibrosis of different aetiologies
The soluble guanylate cyclase stimulator riociguat reduces fibrogenesis and portal pressure in cirrhotic rats
Effects of carbon monoxide-releasing molecules on cGMP levels and soluble guanylate cyclase activity
Effects of age and gender on the pharmacokinetics of the soluble guanylate cyclase stimulator riociguat
Protein kinases G as downstream mediators of the antifibrotic effects of stimulators of soluble guanylate cyclase
Soluble guanylate cyclase stimulator reduced the gastrointestinal fibrosis in bleomycin-induced mouse model of systemic sclerosis
Structural studies of soluble guanylate cyclase
Warfarin pharmacodynamics and pharmacokinetics are not affected by the soluble guanylate cyclase stimulator riociguat (BAY 63-2521)
The CNS-penetrant soluble guanylate cyclase stimulator CYR119 attenuates markers of inflammation in the central nervous system
Pharmacokinetics of the soluble guanylate cyclase stimulator riociguat in individuals with hepatic impairment
From molecules to patients: exploring the therapeutic role of soluble guanylate cyclase stimulators
Pharmacokinetics of the soluble guanylate cyclase stimulator riociguat in individuals with renal impairment
Stimulators of soluble guanylate cyclase (sGC) inhibit experimental skin fibrosis of different aetiologies
The soluble guanylate cyclase stimulator riociguat reduces fibrogenesis and portal pressure in cirrhotic rats
Effects of carbon monoxide-releasing molecules on cGMP levels and soluble guanylate cyclase activity
Effects of age and gender on the pharmacokinetics of the soluble guanylate cyclase stimulator riociguat
Protein kinases G as downstream mediators of the antifibrotic effects of stimulators of soluble guanylate cyclase
Soluble guanylate cyclase stimulator reduced the gastrointestinal fibrosis in bleomycin-induced mouse model of systemic sclerosis
Structural studies of soluble guanylate cyclase
Warfarin pharmacodynamics and pharmacokinetics are not affected by the soluble guanylate cyclase stimulator riociguat (BAY 63-2521)
The CNS-penetrant soluble guanylate cyclase stimulator CYR119 attenuates markers of inflammation in the central nervous system
Pharmacokinetics of the soluble guanylate cyclase stimulator riociguat in individuals with hepatic impairment
From molecules to patients: exploring the therapeutic role of soluble guanylate cyclase stimulators
Pharmacokinetics of the soluble guanylate cyclase stimulator riociguat in individuals with renal impairment
Stimulators of soluble guanylate cyclase (sGC) inhibit experimental skin fibrosis of different aetiologies
The soluble guanylate cyclase stimulator riociguat reduces fibrogenesis and portal pressure in cirrhotic rats
Effects of carbon monoxide-releasing molecules on cGMP levels and soluble guanylate cyclase activity
Effects of age and gender on the pharmacokinetics of the soluble guanylate cyclase stimulator riociguat
Protein kinases G as downstream mediators of the antifibrotic effects of stimulators of soluble guanylate cyclase
Soluble guanylate cyclase stimulator reduced the gastrointestinal fibrosis in bleomycin-induced mouse model of systemic sclerosis
Structural studies of soluble guanylate cyclase
Warfarin pharmacodynamics and pharmacokinetics are not affected by the soluble guanylate cyclase stimulator riociguat (BAY 63-2521)